Study S001383

Evidence Based Evaluation of Incretin Drugs in Reducing the Risk of Cardiovascular and Cerebrovascular Events and Promoting the Remission of Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06959784
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: ENROLLING_BY_INVITATION
Enrollment: 142
Start: 2024-01-01
Primary completion: 2026-12-31
Lead sponsor: China-Japan Friendship Hospital
Conditions: Diabetes Mellitus; Cardiovascular Diseases; Cerebrovascular Disease
Interventions: DRUG:semaglutide; DRUG:Metformin
Results posted: FALSE
Secondary identifiers: OTHER_GRANT:2024-1-4064

Registered primary outcomes

Cardiovascular and cerebrovascular event risk score [One-year follow-up]
Major Adverse Cardiovascular Events [Baseline and every 12 weeks until 96 weeks]
Cerebrovascular disease events [Baseline and every 12 weeks until 96 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.